Vitamin B₃ Supplementation for Optic Neuropathies: A Comprehensive Review

Area of Science:

• Neuroscience
• Ophthalmology
• Cell Biology

Background:

• Optic neuropathies, including glaucoma, are primary causes of irreversible blindness globally.
• Retinal ganglion cell (RGC) loss is a key pathological feature of these conditions.
• Current research seeks effective therapies to mitigate RGC degeneration.

Purpose of the Study:

• To review the impact of vitamin B3 (nicotinamide) on retinal cells, particularly in optic neuropathies.
• To summarize current and future research on vitamin B3's clinical effects in optic neuropathies.
• To provide recommendations on vitamin B3 dosing, efficacy, and side effects.

Main Methods:

• Literature review of existing research on vitamin B3 and optic neuropathies.
• Analysis of vitamin B3's role in mitochondrial metabolism of RGCs.
• Synthesis of clinical trial data and preclinical findings.

Main Results:

• Vitamin B3 enhances mitochondrial metabolism in RGCs, offering neuroprotective potential.
• Emerging evidence suggests vitamin B3 may attenuate RGC loss in optic neuropathies.
• Further clinical studies are needed to confirm efficacy and establish optimal parameters.

Conclusions:

• Vitamin B3 (nicotinamide) presents a promising therapeutic avenue for optic neuropathies.
• Understanding its role in RGC metabolism is crucial for developing new treatments.
• Clinical investigation into vitamin B3's therapeutic potential is warranted.